Relative survival for men and women with type 2 diabetes compared with men and women with the same age from the general population
Men | Women | |||||||||||
Follow-up | N | Death | Lost to follow-up | COS | CES | Relative cumulative survival | N | Death | Lost to follow-up | COS | CES | Relative cumulative survival |
0–1 | 800 | 36 | 1 | 0.96 | 0.97 | 0.99 (0.97–1.00) | 1015 | 35 | 2 | 0.97 | 0.97 | 0.99 (0.98–1.00) |
1–2 | 763 | 38 | 0 | 0.91 | 0.93 | 0.97 (0.95–0.99) | 978 | 32 | 0 | 0.93 | 0.94 | 0.99 (0.97–1.00) |
2–3 | 725 | 38 | 0 | 0.86 | 0.90 | 0.96 (0.93–0.98) | 946 | 53 | 0 | 0.88 | 0.92 | 0.96 (0.94–0.98) |
3–4 | 687 | 28 | 1 | 0.82 | 0.87 | 0.95 (0.92–0.98) | 893 | 40 | 2 | 0.84 | 0.89 | 0.95 (0.92–0.97) |
4–5 | 658 | 31 | 0 | 0.79 | 0.83 | 0.94 (0.91–0.98) | 851 | 41 | 0 | 0.80 | 0.86 | 0.94 (0.91–0.96) |
5–6 | 627 | 35 | 1 | 0.74 | 0.80 | 0.93 (0.89–0.96) | 810 | 52 | 4 | 0.75 | 0.83 | 0.91 (0.88–0.94) |
6–7 | 591 | 30 | 3 | 0.70 | 0.77 | 0.91 (0.87–0.95) | 754 | 33 | 6 | 0.72 | 0.79 | 0.90 (0.87–0.94) |
7–8 | 558 | 26 | 1 | 0.67 | 0.74 | 0.91 (0.86–0.95) | 715 | 40 | 0 | 0.68 | 0.76 | 0.89 (0.85–0.92) |
8–9 | 531 | 22 | 0 | 0.64 | 0.71 | 0.91 (0.86–0.95) | 675 | 38 | 3 | 0.64 | 0.73 | 0.87 (0.83–0.91) |
9–10 | 509 | 20 | 0 | 0.62 | 0.68 | 0.91 (0.86–0.96) | 634 | 30 | 0 | 0.61 | 0.70 | 0.86 (0.82–0.91) |
10–11 | 489 | 15 | 58 | 0.60 | 0.65 | 0.92 (0.86–0.97) | 604 | 35 | 62 | 0.57 | 0.67 | 0.85 (0.80–0.89) |
11–12 | 416 | 22 | 101 | 0.56 | 0.62 | 0.90 (0.85–0.96) | 507 | 28 | 93 | 0.54 | 0.64 | 0.84 (0.79–0.88) |
12–13 | 293 | 17 | 3 | 0.53 | 0.59 | 0.89 (0.83–0.95) | 386 | 26 | 4 | 0.50 | 0.61 | 0.82 (0.77–0.88) |
13–14 | 273 | 16 | 60 | 0.49 | 0.56 | 0.88 (0.81–0.94) | 356 | 18 | 97 | 0.47 | 0.58 | 0.82 (0.76–0.87) |
CES, cumulative expected survival.; COS, cumulative observed survival; N, number of patients at risk.